Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 August 2021 | Story Dikgapane Makhetha | Photo Supplied
Bishop Billyboy Ramahlele (Director: Community Engagement), Napo Masheane (lead actress), and Troy Myeni (Director)

A short fiction film that was shot in Botshabelo and on the Bloemfontein Campus of the UFS, has once again shown the endless possibilities of engaged scholarship in the creative arts.

For this film project, engaged scholarship meant working with graduates / current students from the UFS on projects with a relevant and impactful theme for the broader community. The project was aimed at giving current or past students the opportunity to gain experience or share experience and to transfer skills in the area of filmmaking. 

The short fiction film, Leshano (The Lie), was directed by Mpendulo ‘Troy’ Myeni, a graduate of the UFS Film Programme, who also won an award at the Pan African Film Festival in the US for another of his short films.  Troy was also one of the three co-producers, along with Anton Fisher (a former employee of the UFS), who wrote the script, and Moeketsi Mphunye, a young filmmaker from Botshabelo.
Another notable UFS graduate who was central to the production, is Mbuyiselo Nqodi. He graduated with a BA in Drama and Theatre Arts and has since gone on to make a huge contribution to the performing arts in the Free State and South Africa. Mbuyiselo was the first assistant director of Leshano (The Lie) and had the unenviable job of keeping everything moving on set.  Other members of the production registered at the UFS, but never completed their studies. 

Bishop Billyboy Ramahlele, Director of Community Engagement at the UFS, said he was proud that the UFS could be part of this filmmaking project by making offices available as locations for the film and through the participation of distinguished graduates in key positions of the production.

“The UFS has much to offer young people as students, but also as graduates who seek to advance in their chosen careers. Through community engagement, these young people, whether students or graduates, can be inspired by working with professionals in various fields and gaining hands-on experience. They can then plough back into the community and the UFS.”

“This is the virtuous cycle of community engagement at a university. Students gain knowledge, then they gain inspiration and experience, and plough back into the UFS and broader community, instilling hope for future generations,” Bishop Ramahlele said. 

He added that the UFS would be mentioned in the credits of the film and in publicity and marketing of the film, profiling its reputation as a centre of creative excellence.

Leshano (The Lie) was filmed in Sesotho, with English subtitles, and deals with the important issue of corruption. The lead role is played by the acclaimed Napo Masheane who grew up in Qwaqwa, supported by well-known Free State actors Maria de Koker, Seipati Mpotoane, Ntsiki Ndzume, Vincent Tsoametsi, Pesa Pheko, and Shayne Nketsi. 

Several young, aspiring filmmakers from across the Free State were recruited for the project. It was their first time on the set of a film production, whether as make-up artists, behind the scenes photographers, unit production managers, wardrobe assistants, or location scouts. 

With a strong line-up of women in the lead roles, the film will be released later in August during Women’s Month. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept